Although the goal may be to eventually taper medication, de-prescribing should only occur after durable lifestyle modifications are in place
Allan et al used the TriNetX EHR platform to evaluate the risk of developing dry and wet AMD compared with controls in 9,669 patients taking GLP-1 RA medications
Cells 11 , 2332 (2022)
Central and peripheral nervous system models in rats covering traumatic injury, stroke, and peripheral nerve transection, with cell-survival and tract-tracing endpoints
Taking GLP-1s can increase your risk of developing some health conditions, including diabetic retinopathy, kidney damage, pancreatitis and medullary thyroid cancer
Tirzepatide (Mounjaro, Zepbound) is a peptide-based prescription drug that acts as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management and chronic weight management